Description

[D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors[1][2][3].—COVID-19-immunoregulation–C148H239ClN44O42—-[1]Pozo D, et, al. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. Eur J Pharmacol. 1997 Mar 5; 321(3): 379-86.|[2]Pandol SJ, et, al. Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP. Am J Physiol. 1986 Apr; 250 (4 Pt 1): G553-7.|[3]Messmer B, et, al. Regulation of exocrine pancreatic secretion by cerebral TRH and CGRP: role of VIP, muscarinic, and adrenergic pathways. Am J Physiol. 1993 Feb; 264(2 Pt 1): G237-42.–102805-45-8–3342.20—-O=C([C@H](CC1=CN=CN1)NN[C@H](CO)C(N[C@@H](CC(O)=O)C(N[C@H](C)C(N[C@@H](C(C)C)C(C([C@@H](NCl)CC2=CC=CC=C2)=O)=O)=O)=O)=O)NC([C@H](O)C)C(N[C@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](CC3=CC=C(C=C3)O)C(NC([C@H](O)C)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@H](C)C(N[C@@H](C(C)C)C(N[C@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](CC4=CC=C(C=C4)O)C(N[C@@H](CC(C)C)C(N[C@H](CC(N)=O)C(N[C@@H](CO)C(NC([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@H](CC(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology; Neurological Disease–H2O–Others—-Others–Peptides